Forgetting to inject insulin before meals can be a problem that contributes to long-term complications from diabetes, which is why Medtronic designed a system that it says is the first to recommend ...

With a new smartphone app clearance from the FDA, Medtronic said it has all the pieces necessary to deliver a complete ...

R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its Magnitude drug-eluting bioresorbable scaffold. Mountain View, California-based R3 Vascular ...

Medtronic has also initiated a voluntary field action for its MiniMed™ 600 and 700 series insulin pumps due to potential battery issues. These are all recent developments in Medtronic's journey.

Diabetes shines, cardiac ablation stumbles, and new products spark hope--Medtronic's Q2 FY25 shakes up expectations.

Medtronic (NYSE:MDT) has plans to submit its MiniMed 780G for an expanded indication from the FDA for type 2 diabetes in the near future.

Delivering on commitments, executing ahead of expectations, and raising guidanceInnovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine ...

Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release ...

Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024.

Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation ...